Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma

Klara Kropivšek(SIB Swiss Institute of Bioinformatics), Berend Snijder(SIB Swiss Institute of Bioinformatics), Markus G. Manz(University of Zurich), Paul Kachel(Martin Luther University Halle-Wittenberg), Benjamin D. Hale(SIB Swiss Institute of Bioinformatics), Yasmin Festl(ETH Zurich), Nadja Dietliker(University of Zurich), Sandra Goetze(ETH Zurich), Joëlle Tchinda(University Children's Hospital Zurich), Yannik Severin(SIB Swiss Institute of Bioinformatics), Bernd Wollscheid(SIB Swiss Institute of Bioinformatics), Rebekka Wegmann(ETH Zurich), Julien Mena(ETH Zurich), Audrey van Drogen(SIB Swiss Institute of Bioinformatics)
Nature Cancer
April 20, 2023
10.1038/s43018-023-00544-9
Cited by 42

Related Papers

Mapping human microbiome drug metabolism by gut bacteria and their genes
|Nature|2019|1.1k
Separating host and microbiome contributions to drug pharmacokinetics and toxicity
|Science|2019|427
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
|Cancer Cell|2021|140
European summer climate variability in a heterogeneous multi-model ensemble
|Climatic Change|2007|136
CellSIUS provides sensitive and specific detection of rare cell populations from complex single-cell RNA-seq data
|Genome biology|2019|94